Literature DB >> 19807380

Non-communicating children's pain checklist: better pain assessment for severely disabled children.

Lynn M Breau1.   

Abstract

Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with severe disabilities who are unable to communicate verbally. The non-communicating children's pain checklist-revised has been validated for use with a wide range of pain types in the home. The non-communicating children's pain checklist-postoperative version is used for pain following surgery in the hospital setting. Scores for determining the presence of pain have also been developed. They are appropriate for children with varying degrees of physical, cognitive and communicative impairments.

Entities:  

Year:  2003        PMID: 19807380     DOI: 10.1586/14737167.3.3.327

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  3 in total

1.  [Pain and epilepsy : A clinical, neuroanatomical and pathophysiological review].

Authors:  P Martin
Journal:  Schmerz       Date:  2018-08       Impact factor: 1.107

2.  Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment.

Authors:  Harold B Siden; Bruce C Carleton; Tim F Oberlander
Journal:  Pain Res Manag       Date:  2013-07-24       Impact factor: 3.037

3.  Pain reporting and analgesia management in 270 children with a progressive neurologic, metabolic or chromosomally based condition with impairment of the central nervous system: cross-sectional, baseline results from an observational, longitudinal study.

Authors:  Stefan J Friedrichsdorf; Andrea C Postier; Gail S Andrews; Karen Es Hamre; Rose Steele; Harold Siden
Journal:  J Pain Res       Date:  2017-07-31       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.